Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salirasib in advanced NSCLC
NCT00531401Phase 2Completed
- Sponsor
- Concordia Pharmaceuticals Inc.
- Start
- Sep 2007
- Primary completion
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of salirasib in non-small cell lung cancer (NSCLC), sponsored by Concordia Pharmaceuticals Inc.. Started Sep 2007; status: completed.
02
Drugs
salirasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00531401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00531401.